Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search for
  Limits Preview/Index History Clipboard Details    
About Entrez
spacer gif
back to About Entrez
back to About Entrez

Text Version

Entrez PubMed
Help | FAQ

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries

Related Resources
Order Documents
NLM Gateway
Consumer Health
Clinical Alerts
PubMed Central

Privacy Policy


1: Ann Allergy Asthma Immunol. 2003 May;90(5):572-5. Related Articles, Links

Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration.

Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ.

Department of Medicine, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada.

BACKGROUND: Sustained-release bupropion is commonly used for the symptomatic relief of depressive illness and as an adjuvant in smoking cessation therapy. OBJECTIVE: To report a case of bupropion-induced drug rash with eosinophilia and systemic symptoms syndrome, including acute hepatitis, obstructive lung disease, and myositis. METHODS: After the patient discontinued use of bupropion, serologic tests, muscle biopsies, pulmonary function tests, a chest x-ray examination, venous Doppler ultrasounds, and an electrocardiogram were performed. RESULTS: On discontinuation of bupropion and prolonged systemic corticosteroid therapy, there was complete resolution of symptoms. CONCLUSIONS: To our knowledge, this is the first reported case of drug rash with eosinophilia and systemic symptoms syndrome induced by bupropion therapy. We report this case to notify clinicians of the potential serious multisystem complications that can occur with sustained-release bupropion therapy.

Publication Types:
  • Case Reports

PMID: 12775141 [PubMed - indexed for MEDLINE]